News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

IPO Watch: Affymax, Inc. Aims At Anemia Market


12/1/2006 7:11:55 PM

December 1, 2006 -- Affymax set the terms of its planned IPO, saying it intends to offer 3.5 million shares in a $22-$24 range. After the IPO, the company will have 14 million shares outstanding, giving Affymax a value of $324 million. The lead candidate for Affymax is Hematide, a drug for anemia caused primarily by chronic kidney disease or chemotherapy. The drug is currently undergoing Phase II trials. Affymax signed a monster deal for Hematide with Takeda, getting $122 million upfront, $405 million in milestones, and substantial help in paying for development. We look at the company, its main drug and its finances...

Read at ChinaBio Today

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES